A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Recruiting Phase 2 Interventional Study
Narcolepsy Type 1 Narcolepsy Type 2 Idiopathic Hypersomnia
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
248 (estimated)
Sponsor
Centessa Pharmaceuticals (UK) Limited · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities. While all condition…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 18-65 years of age * BMI ≥17 and ≤37 kg/m2 * Meets the diagnostic criteria of Narcolepsy Type 1 (NT1), Type 2 (NT2) or Idiopathic Hypersomnia (IH) according to ICSD-3-TR criteria * Is willing and able to discontinue all medications used for the treatment of narcolepsy or idiop…
Contacts

Centessa Pharmaceuticals

+1 617-468-5770

CRYSTAL-1@centessa.com

CONTACT